Sogroya

Made by

• Novo Nordisk

Active Ingredient

Somapacitan (genetical recombination)

Prospectus

Approval date

2021/1/22

Treats

• Growth hormone deficiency, Pituitary dwarfism

Dosages

• Sogroya Subcutaneous Injection -

• Sogroya Subcutaneous Injection -